Mirum Pharmaceuticals, Inc. MIRM

A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.

Mirum Pharmaceuticals (MIRM) stock is in focus after the company reported that brelovitug met the primary endpoint in the Phase 3 AZURE-1 trial for chronic hepatitis delta virus, supported by 48-week Phase 2b viral suppression data. Recent headlines around brelovitug and the FDA approval of Atebrioz have arrived after a softer patch for Mirum Pharmaceuticals, with the share price down 9.75% over 30 days and 24.87% over 90 days. Even though year to date the share price return is 12.67% and the...

The U.S. Food and Drug Administration (FDA) on Friday approved Atebrioz (zilurgisertib) tablets, delivering a new once-daily oral treatment to patients suffering from fibrodysplasia ossificans progressiva (FOP). Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and Incyte Corporation (NASDAQ:INCY) announced the regulatory milestone, noting the medication helps reduce the volume of new abnormal bone formation in adults and children aged 12 and older. Read Also: Regeneron Secures FDA Approval For Ultra-Rar

FOSTER CITY, Calif., September 28, 2026--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.

FOSTER CITY, Calif., September 27, 2026--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic HDV on September 28, 2026

FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.

Merck, Mirum, Incyte and Grail are in focus this week as investors await key FDA decisions and a regulatory review involving treatments for lung disease, a rare bone disorder and cancer detection.

Mirum and Incyte are now awaiting the FDA’s decision on zilurgisertib, a once-a-day pill for an ultra-rare bone disease.

FOSTER CITY, Calif., September 14, 2026--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., September 08, 2026--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

FOSTER CITY, Calif., September 02, 2026--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences